Yearly Archives : 2015

A look into…Multiple Myeloma

The International Myeloma Foundation has declared March as ‘Myeloma Awareness Month’. Multiple myeloma (MM) is the second most common haematological malignancy, with an estimated 24,000 new cases reported in 2014 in the US alone. MM is a cancer of the blood which develops in the bone marrow. Normal anti-body producing…

A look into…Neuropathic Pain

October 2014 – October 2015 marks the global year against Neuropathic Pain bringing worldwide attention to a medical condition which affects approximately 47 million people all over the world. Neuropathic pain is defined as a pain which results from damage or disturbance of the central or peripheral nervous system. Physical…

Final voting has commenced for the BOBI Pharma Company and Agency Team Awards

The BOBI voting has opened for the “Agency I would most like to work with”. If your a member of the BHBIA , the team at Black Swan Analysis would greatly appreciate your support in voting for us. We are a small consultancy trying hard to “punch above our weight”…

PATIENT-BASED MODEL TO CHALLENGE PRE-EXISTING EVALUATION OF A NOVEL THERAPEUTIC FOR A POPULATION WITH HIGH UNMET MEDICAL NEED

On March 12, 2015, In Case Studies,
A global biotechnology company had previously assessed the potential acquisition of a product with a novel mechanism of action, for use within a niche population with high unmet medical need. While the acquisition candidate was evaluated and found to fall short of the necessary threshold criteria in terms of forecast revenue potential, a similar asset was subsequently acquired by a top-ten multi-national pharmaceutical company. Our client now wishes to re-explore, in a robust and flexible way, the true potential of the agent for in-licensing. A patient-based model needs to be built, consisting of robust patient populations on which to evaluate…

CONCEPT TESTING OF AN INNOVATIVE IMAGING PLATFORM

On March 12, 2015, In Case Studies,
A market leading device manufacturer is in the process of developing the next generation of imaging technology. The designs are currently at a conceptual stage with the product profile being shaped by both customer insight and views from the development team. With an extended lead time required for both software and industrial design, many of the platform’s features must be agreed upon early in the development process in order to comply with the intended launch date. Qualitative research will be needed to confirm customer acceptance and to pin-point those attributes that will enhance product value. Guidance is needed in identifying…